Differential physiological effects of Raf-1 kinase pathways linked to protein kinase C activation depending on the stimulus in v-H-ras-transformed cells.
OBJECTIVE
We investigated the molecular mechanism by which the Raf-1 kinase pathways that are linked to protein kinase C induce differential physiological effects, depending on the stimulus, by employing the pharmacological PKC activator PMA.


METHODS
Parental and v-Ha-ras transfected NIH 3T3 cells were chosen as test systems and these cells were transiently transfected with the pMTH vector that encodes dominant-negative (DN) PKC-epsilon with using Lipofectamine 2000. The cell proliferation reagent WST-1 was used for the quantitative determination of cellular proliferation. The Raf-1 kinase activity was measured by assessing the phosphorylation of recombinant MEK with using the immunoprecipitated Raf-1 proteins. The phosphorylated MEK protein bands were quantified by using Quantity One analysis software.


RESULTS
The pharmacological PKC activator phorbol-12-myristate-13-acetate (PMA) and platelet-derived growth factor (PDGF) were able to induce the activation of Raf-1 kinase in the v-H-ras-transformed NIH3T3 fibroblasts. However, PMA was found to be much less sensitive PI3 kinase inhibitor or the chemical antioxidant than is PDGF. Especially, PMA mediated growth arrest while PDGF induced mitogenic signaling through the PKC-epsilon activation. Thus, the regulation of the Raf-1 cascade by both PDGF and PMA is likely to be intimately linked and they converge at the PKC level through different upstream pathways, as was shown by the inhibition of PDGF-induced Raf-1 kinase activation by the transient transfection with a dominant-negative mutant of PKC-epsilon.


CONCLUSIONS
Taken together, these results imply that, depending on the stimulus, Raf-1 kinase leads to different physiological effects.
Lee
Michael
M
Department of Biology, College of Natural Sciences, University of Incheon, Incheon, Korea. mikelee@incheon.ac.kr
Biochem Biophys Res Commun. 2003 Nov 28;311(4):1026-33
14623285
J Biol Chem. 2003 Apr 11;278(15):13061-8
12551925
Science. 1984 Sep 21;225(4668):1365-70
6147898
Proc Natl Acad Sci U S A. 1993 Sep 15;90(18):8504-8
8104337
Int J Hematol. 2000 Jul;72(1):12-9
10979203
Cell Cycle. 2007 Jan 1;6(1):3-7
17218791
J Biol Chem. 1996 Jul 26;271(30):18134-9
8663437
Oncogene. 1997 Dec 11;15(24):2921-7
9416835
Cancer Res. 2003 Oct 1;63(19):6547-55
14559850
J Biol Chem. 1993 Mar 25;268(9):6090-6
8454583
Biochem J. 1993 Dec 1;296 ( Pt 2):297-301
8257416
Curr Opin Cell Biol. 1997 Apr;9(2):174-9
9069260
Proc Natl Acad Sci U S A. 1996 Jan 9;93(1):151-5
8552594
J Biol Chem. 1997 Jan 3;272(1):217-21
8995250
Oncogene. 1998 Jun 25;16(25):3345-8
9681835
Mol Membr Biol. 2004 Nov-Dec;21(6):339-49
15764364
Proc Natl Acad Sci U S A. 1983 Jul;80(14):4218-22
6308607
Med Sci Monit. 2006 Oct;12(10):RA220-4
17006414
Cancer Surv. 1996;27:213-48
8909803
Proc Natl Acad Sci U S A. 1997 Oct 14;94(21):11233-7
9326592
Cell. 1989 Aug 25;58(4):649-57
2475255
Mol Cell Biol. 1998 Feb;18(2):790-8
9447975
Science. 1995 Oct 13;270(5234):296-9
7569979
Mol Cell Biol. 1997 Feb;17(2):732-41
9001227
EMBO J. 2000 Feb 15;19(4):496-503
10675318